United Therapeutics Corporation (NASDAQ:UTHR) Q3 2024 Earnings Call Transcript
United Therapeutics Corporation (NASDAQ:UTHR) Q3 2024 Earnings Call Transcript October 30, 2024United Therapeutics Corporation misses on earnings expectations.
United Therapeutics Corp (UTHR)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | VenBio Select Advisor Kurt Von Emster | 2,858,888 | $1,024,482,515 | 14.93% | |
| 2. | Renaissance Technologies Jim Simons | 2,155,392 | $772,384,723 | -1% | 1.16% |
| 3. | AQR Capital Management Cliff Asness | 967,734 | $346,787,479 | +35% | 0.47% |
| 4. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 641,599 | $229,917,002 | +47% | 0.19% |
| 5. | Palo Alto Investors William Leland Edwards | 183,246 | $65,666,204 | -32% | 8.52% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $82.83 | 4 | Director | 1,684 | 2019-06-10 | Filing | |
| $114.06 | 6 | Director | 1,686 | 2018-04-20 | Filing | |
| $126.20 | 5 | Director | 1,685 | 2017-11-20 | Filing | |
| $128.35 | 3 | Director | 1,686 | 2017-07-28 | Filing | |
| $130.24 | 3 | Director | 1,683 | 2017-07-17 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $367.36 | 7,700 | 36,710 | 2024-11-21 | Filing | ||
| $361.86 | 200 | 0 | 2024-11-18 | Filing | ||
| $360.95 | 307 | 200 | 2024-11-18 | Filing | ||
| $359.64 | 500 | 507 | 2024-11-18 | Filing | ||
| $358.89 | 846 | 1,007 | 2024-11-18 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 5,295,000 | $1,164,317,551 | 0.02% | |
| 2. | 4,673,678 | $1,027,695,057 | 0.02% | |
| 3. | 3,794,010 | $834,264,860 | 0.15% | |
| 4. | 2,321,040 | $510,373,376 | 0.03% | |
| 5. | 1,947,177 | $428,164,751 | 0.02% |
News See All
Renaissance Technologies Portfolio: 10 Best Stocks To Buy
Renaissance Technologies is an American hedge fund that specializes in systematic trading and employs statistical and mathematical tools to drive its investment programs.
8 Best Cheap Growth Stocks To Invest In Now
The current market data shows that the economy of the United States is normalizing, especially with an active Federal Reserve, global stimulus from China, and higher consumption rates.
16 Best Mid Cap Growth Stocks To Buy Now
Recent discussions among financial strategists emphasize the current stock market dynamics, particularly regarding the upcoming US elections.
United Therapeutics Corporation (NASDAQ:UTHR) Q2 2024 Earnings Call Transcript
United Therapeutics Corporation (NASDAQ:UTHR) Q2 2024 Earnings Call Transcript July 31, 2024United Therapeutics Corporation misses on earnings expectations.
30 Most Profitable Companies with Highest Margins in the World
In this article, we will be taking a look at the 30 Most Profitable Companies with Highest Margins in the World.
United Therapeutics Corporation (NASDAQ:UTHR) Q1 2024 Earnings Call Transcript
United Therapeutics Corporation beats earnings expectations. Reported EPS is $6.17, expectations were $5.65.
30 Biggest Biotechnology Companies in the World
In this article, we will be taking a look at the 30 biggest biotechnology companies in the world.
5 Most Undervalued Biotech Stocks To Buy According To Hedge Funds
In this article, we discuss 5 most undervalued biotech stocks to buy according to hedge funds.
5 Fastest Growing Biotech Companies in the US
In this article, we will be taking a look at the 5 fastest growing biotech companies in the US.
Billionaire Hedge Funds
